Rockwell Medical announces Phase 3 CRUISE study data accepted as 'Late Breaking'

Rockwell Medical announced that the Phase 3 CRUISE-1 and CRUISE-2 clinical abstract submitted as a Late-Breaking Clinical Trial, or LBCT, to the ASN LBCT subcommittee has been accepted for poster presentation at the ASN Kidney Week 2013 Annual Meeting, November 7-10 in Atlanta, GA. The abstract will be presented under the Late-Breaking Posters as "Continuous, Maintenance Iron Therapy Using Soluble Ferric Pyrophosphate Citrate Chelate Infusion via Hemodialysate in CKD-HD: Phase III CRUISE Studies".

View Comments (0)